Progress in immunotherapy of perioperative esophageal carcinoma
10.3760/cma.j.cn101721-20240404-00109
- VernacularTitle:食管癌围手术期免疫治疗进展
- Author:
Xin DONG
1
;
Shikai WU
;
Xuan JIN
Author Information
1. 北京大学第一医院肿瘤内科，北京 100034
- Keywords:
Esophageal carcinoma;
Squamous cell carcinoma;
Neoadjuvant therapy;
Immune checkpoint inhibitors
- From:
Clinical Medicine of China
2024;40(4):259-264
- CountryChina
- Language:Chinese
-
Abstract:
China is one of the countries with high incidence of esophageal cancer. Different from European and American countries, esophageal squamous cell carcinoma is the main histological classification of esophageal cancer in China. Surgery is the main treatment for non-metastatic esophageal squamous cell carcinoma, but for locally advanced esophageal cancer, surgery alone is not effective. Research has confirmed that neoadjuvant therapy can improve patient survival and has become the standard treatment for locally advanced resectable esophageal cancer patients. With the advent of the era of immunotherapy, the combination of immune checkpoint inhibitors and chemotherapy has become the first-line standard treatment for advanced esophageal cancer. When combined with traditional neoadjuvant therapy, it may bring new hope for the treatment of esophageal cancer. This article reviews the research progress of perioperative immunotherapy strategies for non metastatic esophageal cancer, in order to provide a basis for selecting reasonable treatment plans.
